
EORTC/LinkedIn
Mar 18, 2025, 06:55
EORTC is launching the EORTC-2334-BTG LUMEN-1 clinical trial for recurrent meningioma
EORTC shared a post on LinkedIn:
“New trial alert!
We’re launching the EORTC-2334-BTG LUMEN-1 clinical trial to explore [177Lu] Lu-DOTATATE as a new treatment for recurrent meningioma. This trial will investigate the effectiveness of this new treatment in targeting a specific receptor found in most meningiomas.
It involves 136 patients across 35 sites in 10 European countries, aiming to improve progression-free survival and quality of life.
Learn more about the LUMEN-1 trial.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 18, 2025, 06:48
Mar 18, 2025, 06:38
Mar 18, 2025, 06:38
Mar 18, 2025, 06:28
Mar 18, 2025, 06:21
Mar 18, 2025, 06:20
Mar 17, 2025, 17:39